Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate

    Authors: Yin-Feng Kang; Cong Sun; Zhen Zhuang; Run-Yu Yuan; Qing-Bing Zheng; Ping-Ping Zhou; Jiang-Ping Li; Xin-Chun Chen; Xiao Zhang; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings

    doi:10.1101/2020.11.03.366138 Date: 2020-11-03 Source: bioRxiv

    The ongoing of coronavirus disease 2019 MESHD ( COVID-19 MESHD) pandemic caused by novel SARS-CoV-2 coronavirus MESHD, resulting in economic losses and seriously threating the human health in worldwide, highlighting the urgent need of a stabilized, easily produced and effective preventive vaccine. The SARS-COV-2 spike protein PROTEIN receptor binding region (RBD) plays an important role in the process of viral binding receptor angiotensin-converting enzyme 2 HGNC ( ACE2 HGNC) and membrane fusion, making it an ideal target for vaccine development. In this study, we designed three different RBD-conjugated nanoparticles vaccine candidates, RBD-Ferritin (24-mer), RBD-mi3 (60-mer) and RBD-I53-50 (120-mer), with the application of covalent bond linking by SpyTag-SpyCatcher system. It was demonstrated that the neutralizing capability of sera from mice immunized with three RBD-conjugated nanoparticles adjuvanted with AddaVax or Sigma Systerm Adjuvant ( SAS MESHD) after each immunization was ~8- to 120-fold greater than monomeric RBD group in SARS-CoV-2 pseudovirus MESHD and authentic virus neutralization assay. Most importantly, sera from RBD-conjugated NPs groups more efficiently blocked the binding of RBD to ACE2 HGNC or neutralizing antibody in vitro, a further proof of promising immunization effect. Besides, high physical stability and flexibility in assembly consolidated the benefit for rapid scale-up production of vaccine. These results supported that our designed SARS-CoV-2 RBD-conjugated nanoparticle was competitive vaccine candidate and the carrier nanoparticles could be adopted as universal platform for future vaccine development.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.